Steven R. Schwid

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

Andrew Goodman, Theodore R. Brown, Lauren Krupp et al. · The Lancet · 2009 · 547 citations

Sustained-release Oral Fampridine, Neurological Disorder, Clinical Neurology +8

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Daniel D. Mikol, Frederik Barkhof, Peter Chang et al. · The Lancet Neurology · 2008 · 480 citations

Autoimmune Disease, Disease Progression, Neurological Disorder +8

Cognitive fatigue during a test requiring sustained attention: a pilot study

Steven R. Schwid, Carolyn M. Tyler, Eileen Scheid et al. · Multiple Sclerosis Journal · 2003 · 129 citations

Cognitive function in relapsing multiple sclerosis: Minimal changes in a 10-year clinical trial

Steven R. Schwid, Andrew Goodman, Amy R. Weinstein et al. · Journal of the Neurological Sciences · 2007 · 93 citations

Cognitive Rehabilitation, Neurological Functioning, Minimal Changes +10

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.

Steven R. Schwid, John Thorpe, Mohammad K. Sharief et al. · PubMed · 2005 · 82 citations